HCP 1105

Drug Profile

HCP 1105

Alternative Names: HCP1105

Latest Information Update: 05 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hanmi Pharmaceutical
  • Class Antihyperlipidaemics
  • Mechanism of Action HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Hyperlipidaemia

Most Recent Events

  • 01 Oct 2016 Hanmi Pharmaceuticals completes a phase I trial in Hyperlipidaemia (Combination therapy, In volunteers) in South Korea (NCT02941796)
  • 01 Jul 2016 Phase-I clinical trials in Hyperlipidaemia (In volunteers, Combination therapy) in South Korea (PO) (NCT02941796)
  • 01 Oct 2014 Phase-III clinical trials in Hyperlipidaemia in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top